Monoclonal Antibody to Human Carcinoma-associated Protein Complex: Quantitation in Normal and Tumor Tissue

Ada Sacchi, James Resau, Rita Falcioni, Stephen Kennel

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

We have identified and quantitated a tumor protein complex, TSP-180, on marine carcinomas with two monoclonal antibodies (MoAbs) (Cancer Res., 46: 707–712, 1986). One of the two MoAbs, 135-13C, recognizes a TSP-180-like protein complex on several human carcinomas in culture. MoAb 135-13C has been used to purify the human TSP-180 complex from A431 cells and the purified material used to immunize F344 rats to produce another MoAb, 439-9B, to the human TSP-180 complex. This MoAb does not precipitate the murine TSP-180 or bind to murine cells. Both MoAb 135-13C and 439-9B precipitated the same proteins from A431 cells but did not compete with each other for binding sites, indicating that they recognize different epitopes on the same protein. The two MoAbs have been used in a two-site assay to quantitate TSP-180 proteins on human cells and tissues. Carcinoma cell lines A431, SW948, and A549 all give high values (46 to 443 ng/mg of protein) while murine tumors, a human melanoma, and human fibroblasts are negative (10 ng/mg of protein). Most tissues from autopsy of 2 normal individuals are negative for human TSP-180 at the levels tested (10 ng/mg of protein). Some organs have intermediate range expression: spleen, 5 to 111 ng/ml of protein; colon, 24 to 111; and small intestine, 39 to 99. One primary colon and one larynx tumor were positive (144 to 372 ng/mg of protein) while 5 breast carcinomas, a stomach tumor, a metastatic melanoma, and a kidney tumor were negative. These data indicate that human TSP-180 may be preferentially expressed in certain malignant carcinomas of diverse origin. The potential for TSP-180 as a tumor marker requires further study.

Original languageEnglish (US)
Pages (from-to)816-821
Number of pages6
JournalCancer Research
Volume48
Issue number4
StatePublished - 1988
Externally publishedYes

Fingerprint

Integrin alpha6beta4
Monoclonal Antibodies
Carcinoma
Neoplasms
Proteins
Melanoma
Colon
Inbred F344 Rats
Tumor Biomarkers
Larynx
Small Intestine
Epitopes
Autopsy
Stomach

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Monoclonal Antibody to Human Carcinoma-associated Protein Complex : Quantitation in Normal and Tumor Tissue. / Sacchi, Ada; Resau, James; Falcioni, Rita; Kennel, Stephen.

In: Cancer Research, Vol. 48, No. 4, 1988, p. 816-821.

Research output: Contribution to journalArticle

@article{038aec860614432492041d9a99a44a92,
title = "Monoclonal Antibody to Human Carcinoma-associated Protein Complex: Quantitation in Normal and Tumor Tissue",
abstract = "We have identified and quantitated a tumor protein complex, TSP-180, on marine carcinomas with two monoclonal antibodies (MoAbs) (Cancer Res., 46: 707–712, 1986). One of the two MoAbs, 135-13C, recognizes a TSP-180-like protein complex on several human carcinomas in culture. MoAb 135-13C has been used to purify the human TSP-180 complex from A431 cells and the purified material used to immunize F344 rats to produce another MoAb, 439-9B, to the human TSP-180 complex. This MoAb does not precipitate the murine TSP-180 or bind to murine cells. Both MoAb 135-13C and 439-9B precipitated the same proteins from A431 cells but did not compete with each other for binding sites, indicating that they recognize different epitopes on the same protein. The two MoAbs have been used in a two-site assay to quantitate TSP-180 proteins on human cells and tissues. Carcinoma cell lines A431, SW948, and A549 all give high values (46 to 443 ng/mg of protein) while murine tumors, a human melanoma, and human fibroblasts are negative (10 ng/mg of protein). Most tissues from autopsy of 2 normal individuals are negative for human TSP-180 at the levels tested (10 ng/mg of protein). Some organs have intermediate range expression: spleen, 5 to 111 ng/ml of protein; colon, 24 to 111; and small intestine, 39 to 99. One primary colon and one larynx tumor were positive (144 to 372 ng/mg of protein) while 5 breast carcinomas, a stomach tumor, a metastatic melanoma, and a kidney tumor were negative. These data indicate that human TSP-180 may be preferentially expressed in certain malignant carcinomas of diverse origin. The potential for TSP-180 as a tumor marker requires further study.",
author = "Ada Sacchi and James Resau and Rita Falcioni and Stephen Kennel",
year = "1988",
language = "English (US)",
volume = "48",
pages = "816--821",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Monoclonal Antibody to Human Carcinoma-associated Protein Complex

T2 - Quantitation in Normal and Tumor Tissue

AU - Sacchi, Ada

AU - Resau, James

AU - Falcioni, Rita

AU - Kennel, Stephen

PY - 1988

Y1 - 1988

N2 - We have identified and quantitated a tumor protein complex, TSP-180, on marine carcinomas with two monoclonal antibodies (MoAbs) (Cancer Res., 46: 707–712, 1986). One of the two MoAbs, 135-13C, recognizes a TSP-180-like protein complex on several human carcinomas in culture. MoAb 135-13C has been used to purify the human TSP-180 complex from A431 cells and the purified material used to immunize F344 rats to produce another MoAb, 439-9B, to the human TSP-180 complex. This MoAb does not precipitate the murine TSP-180 or bind to murine cells. Both MoAb 135-13C and 439-9B precipitated the same proteins from A431 cells but did not compete with each other for binding sites, indicating that they recognize different epitopes on the same protein. The two MoAbs have been used in a two-site assay to quantitate TSP-180 proteins on human cells and tissues. Carcinoma cell lines A431, SW948, and A549 all give high values (46 to 443 ng/mg of protein) while murine tumors, a human melanoma, and human fibroblasts are negative (10 ng/mg of protein). Most tissues from autopsy of 2 normal individuals are negative for human TSP-180 at the levels tested (10 ng/mg of protein). Some organs have intermediate range expression: spleen, 5 to 111 ng/ml of protein; colon, 24 to 111; and small intestine, 39 to 99. One primary colon and one larynx tumor were positive (144 to 372 ng/mg of protein) while 5 breast carcinomas, a stomach tumor, a metastatic melanoma, and a kidney tumor were negative. These data indicate that human TSP-180 may be preferentially expressed in certain malignant carcinomas of diverse origin. The potential for TSP-180 as a tumor marker requires further study.

AB - We have identified and quantitated a tumor protein complex, TSP-180, on marine carcinomas with two monoclonal antibodies (MoAbs) (Cancer Res., 46: 707–712, 1986). One of the two MoAbs, 135-13C, recognizes a TSP-180-like protein complex on several human carcinomas in culture. MoAb 135-13C has been used to purify the human TSP-180 complex from A431 cells and the purified material used to immunize F344 rats to produce another MoAb, 439-9B, to the human TSP-180 complex. This MoAb does not precipitate the murine TSP-180 or bind to murine cells. Both MoAb 135-13C and 439-9B precipitated the same proteins from A431 cells but did not compete with each other for binding sites, indicating that they recognize different epitopes on the same protein. The two MoAbs have been used in a two-site assay to quantitate TSP-180 proteins on human cells and tissues. Carcinoma cell lines A431, SW948, and A549 all give high values (46 to 443 ng/mg of protein) while murine tumors, a human melanoma, and human fibroblasts are negative (10 ng/mg of protein). Most tissues from autopsy of 2 normal individuals are negative for human TSP-180 at the levels tested (10 ng/mg of protein). Some organs have intermediate range expression: spleen, 5 to 111 ng/ml of protein; colon, 24 to 111; and small intestine, 39 to 99. One primary colon and one larynx tumor were positive (144 to 372 ng/mg of protein) while 5 breast carcinomas, a stomach tumor, a metastatic melanoma, and a kidney tumor were negative. These data indicate that human TSP-180 may be preferentially expressed in certain malignant carcinomas of diverse origin. The potential for TSP-180 as a tumor marker requires further study.

UR - http://www.scopus.com/inward/record.url?scp=0023876483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023876483&partnerID=8YFLogxK

M3 - Article

C2 - 2448027

AN - SCOPUS:0023876483

VL - 48

SP - 816

EP - 821

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -